Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Adaptive Biotechnologies Soared 61.7% in the First Half of 2020

By Maxx Chatsko – Jul 9, 2020 at 3:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors expect the company's technology platform to come in handy as the world corrals the coronavirus pandemic.

What happened

Shares of Adaptive Biotechnologies (ADPT 3.94%) rose over 61% in the first six months of the year, according to data provided by S&P Global Market Intelligence. That was easily better than the 4% decline of the S&P 500 in that span.

The stock had been mired in a near-continuous slide from its initial public offering last summer through this March, but that changed when the company pledged to throw its technology platform at the coronavirus pandemic. Can the growth stock continue its momentum in the second half of 2020?

A businessman riding a cartoon rocket.

Image source: Getty Images.

So what

Adaptive Biotechnologies is developing a technology platform that mines and maps biological data related to the adaptive immune system. Considering the role of the adaptive immune system in COVID-19 progression and recovery, it makes sense for researchers to leverage the company's platform to better understand the health crisis.

Adaptive Biotechnologies teamed up with Microsoft, LabCorp, Illumina, and others to combine population-level data in an attempt to discover insights that could influence public health decisions and drug development. The findings, part of the ImmuneCODE database, have been made freely available to researchers across the globe. Meanwhile, the data-mining company is also working with Amgen to discover therapeutic antibodies against SARS-CoV-2.

Now what

Investors might not want to get too carried away. Adaptive Biotechnologies cannot directly monetize its contributions to the ImmuneCODE. Of course, that's not the point, but the share price suggests not everyone is aware of that reality. Given the fact the business is reporting widening operating losses as it scales its platform, a lot of future potential is already baked into the current $6.2 billion valuation.

Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Illumina and Microsoft. The Motley Fool recommends Amgen and recommends the following options: short January 2021 $115 calls on Microsoft and long January 2021 $85 calls on Microsoft. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Adaptive Biotechnologies Corporation Stock Quote
Adaptive Biotechnologies Corporation
$7.12 (3.94%) $0.27
Microsoft Corporation Stock Quote
Microsoft Corporation
$232.90 (-1.94%) $-4.60
Amgen Inc. Stock Quote
Amgen Inc.
$225.40 (-1.32%) $-3.01
Illumina, Inc. Stock Quote
Illumina, Inc.
$190.79 (-1.56%) $-3.02
Laboratory Corporation of America Holdings Stock Quote
Laboratory Corporation of America Holdings
$204.81 (-1.53%) $-3.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.